U.S. Markets open in 4 hrs 32 mins
  • S&P Futures

    3,780.50
    -40.75 (-1.07%)
     
  • Dow Futures

    30,740.00
    -259.00 (-0.84%)
     
  • Nasdaq Futures

    11,536.00
    -155.00 (-1.33%)
     
  • Russell 2000 Futures

    1,701.50
    -19.90 (-1.16%)
     
  • Crude Oil

    109.60
    -0.18 (-0.16%)
     
  • Gold

    1,816.80
    -0.70 (-0.04%)
     
  • Silver

    20.69
    -0.05 (-0.23%)
     
  • EUR/USD

    1.0443
    -0.0001 (-0.0104%)
     
  • 10-Yr Bond

    3.0930
    0.0000 (0.00%)
     
  • Vix

    29.28
    +0.92 (+3.24%)
     
  • GBP/USD

    1.2143
    +0.0020 (+0.1676%)
     
  • USD/JPY

    136.2400
    -0.3050 (-0.2234%)
     
  • BTC-USD

    19,272.23
    -740.33 (-3.70%)
     
  • CMC Crypto 200

    414.12
    -25.55 (-5.81%)
     
  • FTSE 100

    7,198.65
    -113.67 (-1.55%)
     
  • Nikkei 225

    26,393.04
    -411.56 (-1.54%)
     

Evolus to Report First Quarter 2021 Results and Provide Business Update

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

NEWPORT BEACH, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced today that it will report its first quarter 2021 financial results and provide a business update on Wednesday, May 12, 2021, after the close of the U.S. financial markets.

Management will host a conference call and live webcast to discuss Evolus’ financial results at 4:30 p.m. ET that same day. A question and answer session will follow management remarks.

The dial-in numbers for the conference call are (866) 916-2317 for domestic callers and (703) 925-2662 for international callers. The conference ID is 7749489.

A replay of the call will be available following its completion through May 19, 2021. To access the replay, dial (855) 859-2056 for domestic callers and (404) 537-3406 for international callers and use the replay conference ID 7749489.

A live audio webcast of the call will be available on the Investor Relations page of the Evolus, Inc. website, https://investors.evolus.com. A replay of the webcast will be archived on Evolus' website for 30 days following the completion of the call.

About Evolus, Inc.

Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S. Food and Drug Administration approved Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau® is powered by Evolus' unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us at: http://www.evolus.com.

Jeuveau® is a registered trademark of Evolus, Inc.

Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.

Investor Contact
The Ruth Group
Christine Petraglia
Senior Vice President
Tel: 917-633-8980
Email: cpetraglia@theruthgroup.com